Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

mTORC1 inhibitor

DRUG CLASS:

mTORC1 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: B - Late Trials CB-228 Sensitive : B	CB-228 Sensitive: B - Late Trials CB-228 Sensitive : B
No biomarker	Sarcoma	No biomarker	Sarcoma	nanoparticle albumin-bound rapamycin Sensitive: B - Late Trials nanoparticle albumin-bound rapamycin Sensitive : B	nanoparticle albumin-bound rapamycin Sensitive: B - Late Trials nanoparticle albumin-bound rapamycin Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
KEAP1 mutation	Lung Non-Small Cell Squamous Cancer	KEAP1 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
NFE2L2 mutation	Lung Cancer	NFE2L2 mutation	Lung Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	tamoxifen + CB-228 Sensitive: C3 – Early Trials tamoxifen + CB-228 Sensitive : C3	tamoxifen + CB-228 Sensitive: C3 – Early Trials tamoxifen + CB-228 Sensitive : C3
PTEN deletion	Colorectal Cancer	PTEN deletion	Colorectal Cancer	bevacizumab + nanoparticle albumin-bound rapamycin Sensitive: C3 – Early Trials bevacizumab + nanoparticle albumin-bound rapamycin Sensitive : C3	bevacizumab + nanoparticle albumin-bound rapamycin Sensitive: C3 – Early Trials bevacizumab + nanoparticle albumin-bound rapamycin Sensitive : C3
NFE2L2 E79K	Lung Non-Small Cell Squamous Cancer	NFE2L2 E79K	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
AKT1 mutation + HR positive	HER2 Negative Breast Cancer	AKT1 mutation + HR positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
EWSR1-POU5F1 fusion	Renal Cell Carcinoma	EWSR1-POU5F1 fusion	Renal Cell Carcinoma	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
AKT1 mutation + mTOR mutation	Leiomyosarcoma	AKT1 mutation + mTOR mutation	Leiomyosarcoma	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3